NOTE 6 – INTANGIBLE ASSET

The Company has capitalized the costs associated with acquiring the exclusive worldwide license to develop and commercialize products comprising or containing the compound ART27.13 as an intangible asset at a value of $2,039 as of December 31, 2022, December 31, 2021, and August 31, 2021. 

The amount capitalized consisted of a $1,500 payment and the fair value of 4,087 shares of common stock of $539. During the year ended December 31, 2022, the four months ended December 31, 2021, and the year ended August 31, 2021, no additional costs met the criteria for capitalization as an intangible asset.